Did medicare induce pharmaceutical innovation?

被引：35
作者：
Acemoglu, Daron
Cutler, David
Finkelstein, Amy
Linn, Joshua
机构：
[1] MIT, Dept Econ, Cambridge, MA 02142 USA
[2] MIT, NBER, Cambridge, MA 02142 USA
[3] Harvard Univ, Dept Econ, Cambridge, MA 02138 USA
[4] NBER, Littauer Ctr, Cambridge, MA 02138 USA
[5] MIT, Dept Econ, Cambridge, MA 02138 USA
[6] Univ Illinois, Dept Econ, Chicago, IL 60607 USA
来源：
AMERICAN ECONOMIC REVIEW | 2006年 / 96卷 / 02期
关键词：
D O I：
10.1257/000282806777211766
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：103 / 107
页数：5
相关论文
共 11 条
[1]   Market size in innovation: Theory and evidence from the pharmaceutical industry [J].
Acemoglu, D ;
Linn, J .
QUARTERLY JOURNAL OF ECONOMICS, 2004, 119 (03) :1049-1090
[2]  
ACEMOGLU D, IN PRESS DID MEDICAR
[3]  
COOK B, 2005, UNPUB IMPACT MEDICAR
[4]  
Cutler D., 2004, YOUR MONEY YOUR LIFE
[5]  
Cutler DM, 2003, MEASURING THE GAINS FROM MEDICAL RESEARCH, P110
[6]   COST OF INNOVATION IN THE PHARMACEUTICAL-INDUSTRY [J].
DIMASI, JA ;
HANSEN, RW ;
GRABOWSKI, HG ;
LASAGNA, L .
JOURNAL OF HEALTH ECONOMICS, 1991, 10 (02) :107-142
[7]   Static and dynamic effects of health policy: Evidence from the vaccine industry [J].
Finkelstein, A .
QUARTERLY JOURNAL OF ECONOMICS, 2004, 119 (02) :527-564
[8]  
Finkelstein A., 2005, 11609 NBER
[9]  
FINKELSTEIN A, 2005, 11619 NBER
[10]  
Lichtenberg FR, 2004, PUBLIC POLICY AND THE ECONOMICS OF ENTREPRENEURSHIP, P83
12